Equities Analysts Offer Predictions for ALNY Q3 Earnings

Key Points

• The investment firm Leerink Partners has raised its Q3 2025 earnings estimate for Alnylam Pharmaceuticals, now predicting earnings of $0.38 per share, a significant increase from a previous forecast of ($0.24).
• Alnylam Pharmaceuticals recently reported a $0.32 earnings per share, surpassing the consensus estimate of ($0.54) by $0.86, along with a year-over-year revenue increase of 17.3%.
• Multiple analysts have upgraded their price targets for Alnylam Pharmaceuticals, with estimates now ranging from $390.00 to as high as $490.00, reflecting strong overall investor sentiment.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Leerink Partnrs lifted their Q3 2025 earnings estimates for Alnylam Pharmaceuticals in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now expects that the biopharmaceutical company will earn $0.38 per share for the quarter, up from their previous forecast of ($0.24). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $6.62 EPS and FY2027 earnings at $11.31 EPS.

Other research analysts also recently issued research reports about the company. Oppenheimer raised Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price for the company in a research note on Monday, August 4th. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price for the company. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Finally, BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. Four investment analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $403.92.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $2.71 on Monday, hitting $432.64. 1,560,438 shares of the stock were exchanged, compared to its average volume of 946,827. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $445.20. The business has a 50-day moving average of $336.89 and a two-hundred day moving average of $286.99. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market capitalization of $56.71 billion, a price-to-earnings ratio of -175.33 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of ALNY. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $27,000. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $28,000. Whipplewood Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $30,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.